📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 18:50
1 analysed today
FollowTelegram
1
Today
151,861
All-time analysed
43,535
Positive
6,743
Negative
92,746
Neutral
8,769
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
23 announcements match the current filters (relevance ≥ 5).
Albert David Approves ₹5.00 Dividend and Appoints New CEO for 5-Year Term
Albert David Limited's shareholders approved all seven resolutions at the 87th AGM held on August 6, 2026. Key outcomes include the declaration of a ₹5.00 per share dividend for FY26 and the formal appointment of Mr. Amit Mahla as CEO and Whole-time Director for a five-year term. The company also ratified a revision in remuneration for the Executive Chairman, Mr. Arun Kumar Kothari, for FY27. Voting participation was consistent, with approximately 64.61% of the total 57.07 lakh issued shares represented in the poll.
Confidence: HIGH
What changedThe company has transitioned to a new CEO, Mr. Amit Mahla, and formalized its dividend payout and executive compensation structure for the upcoming fiscal year.
Why it mattersThe formalization of a 5-year CEO term provides leadership stability, while the dividend maintains shareholder returns despite the company's low ROCE and product concentration risks in placenta-based drugs.
Dividend per share: ₹5.00CEO Appointment Tenure: 5 yearsCost Auditor Remuneration: ₹70,000Total Issued Shares: 57,07,162Voting Turnout: 64.61%
📅 Short termNeutral; the stock may see minor activity around the dividend payout, but the AGM results were largely procedural and expected.
📈 Long termThe long-term outlook depends on the new CEO's ability to diversify the product pipeline beyond placenta-based drugs and improve manufacturing efficiency through the planned technology upgrades.
⚠ Risk flags
- Low ROCE of 1.0%
- High product concentration in placenta-based drugs
- Regulatory risks associated with pharmaceutical manufacturing standards
Key Highlights
Approved a dividend of ₹5.00 per equity share of ₹10 face value for the financial year ended March 31, 2026.
Appointed Mr. Amit Mahla as Whole-time Director and CEO for a 5-year term from June 19, 2026, to June 18, 2031.
Ratified the remuneration of Cost Auditors for FY27 at ₹70,000 plus applicable taxes.
Total votes polled for the adoption of FY26 financials stood at 36,87,639, representing 64.61% of issued shares.
Approved the re-appointment of Mrs. Prabhawati Devi Kothari as a Director following her retirement by rotation.
👀 What to Watch
Investors should monitor the strategic direction under the new CEO, Mr. Amit Mahla, particularly regarding the company's stated goal of upgrading facilities to Revised Schedule-M standards and improving the current 1.0% ROCE.
₹5 Dividend and CEO Appointment Confirmed at Albert David's 87th AGM
Albert David Limited concluded its 87th Annual General Meeting on August 6, 2026, where shareholders approved a dividend of ₹5 per equity share for FY26. A significant leadership transition was formalized with the appointment of Mr. Amit Mahla as Whole-time Director & CEO for a five-year term ending June 2031. Additionally, shareholders voted on the revision of remuneration for Executive Chairman Mr. Arun Kumar Kothari and the ratification of cost auditors for FY27. The meeting also adopted the audited financial statements for the year ended March 31, 2026.
Confidence: HIGH
What changedThe company has formalized its top leadership structure for the next five years and confirmed the dividend payout for the previous fiscal year.
Why it mattersLeadership continuity under a new CEO is critical as the company navigates facility upgrades and R&D for new molecules. The dividend provides a tangible return to shareholders from the FY26 earnings.
Dividend per share: ₹5CEO Appointment Term: 5 yearsCut-off Date: July 30, 2026Face Value: ₹10Debt: ₹30 Cr
📅 Short termThe stock price may reflect the dividend confirmation in the coming weeks as the payout process initiates.
📈 Long termThe five-year CEO mandate provides structural stability for the company's long-term goal of penetrating new markets and strengthening its product pipeline.
⚠ Risk flags
- Executive remuneration revisions (Special Resolution)
- Product concentration risk in placenta-based drugs
Key Highlights
Approved a dividend of ₹5 per equity share of ₹10 face value for FY26
Appointed Mr. Amit Mahla as Whole-time Director & CEO for a 5-year term from June 19, 2026, to June 18, 2031
Revised remuneration for Executive Chairman Mr. Arun Kumar Kothari for the period April 1, 2026, to March 31, 2027
Established July 30, 2026, as the cut-off date for shareholder voting eligibility
Adopted audited financial statements and reports for the fiscal year ended March 31, 2026
👀 What to Watch
Investors should monitor the final voting results for any significant dissent regarding executive remuneration revisions. The focus should remain on the new CEO's ability to execute the company's strategy of upgrading facilities to Revised Schedule-M standards.
Resignation of Head of R&D Dr. Kuntal Ganguly Effective August 5, 2026
Albert David Limited has announced the resignation of Dr. Kuntal Ganguly, the Head of Research & Development (R&D), effective from the close of business on August 5, 2026. The resignation is attributed to personal reasons. This departure is notable as the company's qualitative strategy emphasizes R&D focus on new molecules and drug delivery systems to drive future growth. No immediate successor has been named in the filing.
Confidence: HIGH
What changedThe leadership of the Research & Development department has become vacant following the resignation of Dr. Kuntal Ganguly.
Why it mattersFor a pharmaceutical company focused on upgrading manufacturing standards and developing new drug delivery systems, the Head of R&D is a critical role for maintaining the product pipeline and long-term competitiveness.
Effective Date of Cessation: August 5, 2026Net Worth: Rs 392 CrDebt: Rs 30 CrPromoter Holding: 62.24%
📅 Short termThe stock may see neutral to cautious sentiment as the market evaluates the impact of leadership turnover in a core technical function.
📈 Long termThe long-term impact depends on the company's ability to recruit a qualified successor to lead its R&D-driven growth and diversification strategy.
⚠ Risk flags
- Key person dependency in R&D
- Potential delay in new product pipeline development
Key Highlights
Dr. Kuntal Ganguly resigned from the position of Head-R&D effective August 5, 2026
The resignation was submitted due to personal reasons as per the official disclosure
Company strategy relies on R&D for new molecules to mitigate product concentration risk in placenta-based drugs
Albert David maintains a net worth of Rs 392 Cr with a relatively low debt of Rs 30 Cr
👀 What to Watch
Investors should watch for the appointment of a new R&D head and any updates regarding the timeline for new molecule development or facility upgrades to Revised Schedule-M standards.
Albert David Submits Q1 FY2026-27 Results; Board Meeting Concluded on Aug 6
Albert David Limited has released its unaudited financial results for the quarter ended June 30, 2026. The board meeting, held on August 6, 2026, lasted approximately 3 hours and 40 minutes. The company maintains a conservative capital structure with a debt of Rs 30 Cr against a net worth of Rs 392 Cr (D/E ratio of 0.08). Investors should monitor the detailed P&L for improvements in ROCE, which was recently reported at a low 1.0%.
Confidence: MEDIUM
What changedThe company has formally reported its financial performance for the first quarter of the 2026-27 fiscal year, following board approval.
Why it mattersThis is a routine but essential disclosure that provides transparency into the company's current financial health and its progress on upgrading manufacturing units for cost control.
Debt: Rs 30 CrNet Worth: Rs 392 CrDebt/Equity Ratio: 0.08Promoter Holding: 62.24%ROCE: 1.0%
📅 Short termThe stock may see neutral to range-bound movement as the market digests the specific revenue and profit figures from the detailed filing.
📈 Long termLong-term value depends on the company's ability to diversify its product pipeline and improve its low ROCE through better manufacturing efficiency and market expansion.
⚠ Risk flags
- Product concentration risk (placenta-based drugs)
- Low ROCE of 1.0%
- Regulatory risks inherent to pharmaceutical manufacturing
Key Highlights
Board meeting conducted on August 6, 2026, from 11:35 A.M. to 3:15 P.M.
Unaudited financial results submitted for the quarter ended June 30, 2026.
Company debt stands at Rs 30 Cr against a net worth of Rs 392 Cr.
Promoter holding remains stable at 62.24% as of the June 2026 quarter.
Company is targeting a 9.80% growth rate through facility upgrades to Revised Schedule-M standards.
👀 What to Watch
Review the full financial tables for revenue growth and operating margins to see if R&D investments in new molecules are offsetting product concentration risks in placenta-based drugs.
Albert David Credit Ratings Reaffirmed at 'CARE A'; Outlook Remains Negative
CARE EDGE Ratings has reaffirmed Albert David Limited's long-term rating at 'CARE A' and short-term rating at 'CARE A1'. The outlook for the long-term facilities remains 'Negative', indicating potential risks to the company's credit profile or financial performance. The total rated bank facilities have been slightly reduced to ₹62.50 crore from the previous ₹64.50 crore. This review follows the assessment of the company's financial performance for the fiscal year 2026.
Key Highlights
Long-term bank facilities of ₹50.50 crore reaffirmed at 'CARE A' with a 'Negative' outlook.
Short-term bank facilities of ₹12.00 crore reaffirmed at 'CARE A1'.
Total rated bank facilities decreased by ₹2.00 crore, from ₹64.50 crore to ₹62.50 crore.
Rating review was based on the company's operational and financial performance for FY26.
👀 What to Watch
Investors should monitor the company's upcoming financial results to see if operational performance improves enough to stabilize the 'Negative' outlook. While the reaffirmation shows current stability, the outlook suggests a need for caution regarding future credit health.
Albert David Appoints Amit Mahla as Whole-time Director & CEO for 5-Year Term
Albert David Limited has officially appointed Mr. Amit Mahla as an Additional Director and Whole-time Director & CEO for a five-year tenure effective June 19, 2026. Mr. Mahla, who has served as the company's CEO since May 12, 2026, brings over 28 years of experience from major pharmaceutical firms including Cipla, Sun Pharma, and JB Pharma. The appointment and his remuneration for the period ending March 31, 2027, are subject to shareholder approval at the upcoming 87th Annual General Meeting. This move is aimed at leveraging his expertise in business transformation and strategic leadership within the Indian Pharmaceutical Market.
Key Highlights
Appointment of Mr. Amit Mahla as Whole-time Director & CEO for a 5-year term from June 19, 2026, to June 18, 2031.
Mr. Mahla possesses over 28 years of industry experience with leadership roles at Cipla, Sun Pharma, and JB Pharma.
The Board has revised the 87th AGM notice to include shareholder approval for this appointment and remuneration fixation.
The appointee previously led the integration of Sanzyme into JB Pharma, demonstrating high-level M&A and integration expertise.
Remuneration for the initial period from June 19, 2026, to March 31, 2027, has been approved by the Board.
👀 What to Watch
Investors should monitor the upcoming 87th AGM for shareholder approval of the appointment, as Mr. Mahla's extensive background in top-tier pharma companies could signal a strategic growth phase for the company.
Albert David Appoints Amit Mahla as Whole-time Director & CEO for 5-Year Term
Albert David Limited has officially appointed Mr. Amit Mahla as an Additional Director and Whole-time Director & CEO for a five-year tenure starting June 19, 2026. Mr. Mahla, who has been serving as CEO since May 12, 2026, brings over 28 years of industry experience from major firms like Sun Pharma, Cipla, and JB Pharma. The appointment is subject to shareholder approval at the upcoming 87th Annual General Meeting. This move aims to leverage his expertise in business transformation and strategic leadership within the Indian Pharmaceutical Market.
Key Highlights
Appointment of Amit Mahla as Whole-time Director & CEO for a 5-year term ending June 18, 2031.
Mr. Mahla possesses over 28 years of experience in the pharmaceutical sector with a track record of building 20+ major brands.
Previous leadership experience includes roles at top-tier companies such as Sun Pharma, Glenmark, and JB Pharma.
The Board has revised the 87th AGM notice to include shareholder approval for his appointment and remuneration.
Mr. Mahla is recognized for leading the integration of Sanzyme into JB Pharma, a major recent acquisition in the industry.
👀 What to Watch
Investors should view this as a positive step toward professionalizing management with a seasoned industry veteran. Monitor upcoming quarterly results to see if his strategic leadership translates into improved growth and business transformation.
Albert David Appoints Amit Mahla as Whole-time Director & CEO for 5-Year Term
Albert David Limited has elevated its CEO, Mr. Amit Mahla, to the position of Whole-time Director & CEO for a five-year tenure effective June 19, 2026, to June 18, 2031. Mr. Mahla, who joined the company as CEO in May 2026, brings over 28 years of experience from major pharmaceutical firms including Sun Pharma, Cipla, and JB Pharma. The Board has also fixed his remuneration through March 31, 2027, and revised the 87th AGM notice to seek shareholder approval for these appointments. This leadership move is intended to drive business transformation and strategic growth.
Key Highlights
Mr. Amit Mahla appointed as Whole-time Director & CEO for a 5-year term ending June 18, 2031.
The appointee has over 28 years of experience in the Indian Pharmaceutical Market, with prior leadership roles at JB Pharma and Sun Pharma.
Remuneration for the period June 19, 2026, to March 31, 2027, has been approved by the Board.
The 87th AGM notice has been revised to include shareholder approval for the regularization of this appointment.
Mr. Mahla is recognized for brand building and successfully leading the Sanzyme integration into JB Pharma.
👀 What to Watch
Investors should view this as a positive step toward professionalizing management with a seasoned industry veteran; monitor upcoming quarterly results for signs of strategic shifts under his leadership.
Albert David Reports Q4 Net Loss of ₹21.43 Cr Impacted by Negative Other Income
Albert David Limited reported a significant net loss of ₹21.43 crore for the quarter ended March 31, 2026, primarily driven by an unusual negative 'Other Income' figure of ₹24.84 crore. For the full financial year 2025-26, the company posted a consolidated net loss of ₹1.49 crore on a total revenue from operations of ₹333.60 crore. Despite the bottom-line pressure, the company maintains a robust liquidity position with current investments valued at ₹225.05 crore. The quarterly EPS stood at a negative ₹37.56, reflecting the sharp downturn in profitability during the final period.
Key Highlights
Q4 FY26 revenue from operations was ₹85.86 crore, but total income dropped to ₹61.03 crore due to negative other income.
Net loss for Q4 FY26 stood at ₹21.43 crore, leading to a full-year net loss of ₹1.49 crore.
Total expenses for the full year FY26 were ₹340.53 crore against a total income of ₹341.05 crore.
Strong balance sheet maintained with total equity of ₹391.54 crore and current investments of ₹225.05 crore.
Basic and Diluted EPS for the full year FY26 ended at negative ₹2.62.
👀 What to Watch
Investors should seek clarification regarding the significant negative 'Other Income' of ₹24.84 crore in Q4, which appears to be a non-operational write-down or adjustment. While the core pharmaceutical operations remain steady, the sudden quarterly loss warrants a cautious approach until the nature of the income adjustment is understood.
Albert David Appoints Amit Mahla as CEO; Recommends Rs 5.00 Final Dividend
Albert David Limited has appointed Mr. Amit Mahla as the new CEO, bringing over 28 years of experience from top pharma firms like Sun Pharma and JB Pharma. The Board recommended a final dividend of Rs. 5.00 per share (50% of face value) for FY 2025-26, with a record date set for July 30, 2026. The company reported audited financial results for the year ended March 31, 2026, with an unmodified audit opinion from M/s. L. B. Jha & Co. Additionally, PwC Services LLP has been re-appointed as internal auditors for the upcoming fiscal year.
Key Highlights
Appointment of Mr. Amit Mahla as CEO effective May 12, 2026, bringing 28+ years of pharma experience from Cipla, Sun Pharma, and JB Pharma.
Recommended a final dividend of Rs. 5.00 per equity share (50% of face value) for the financial year ended March 31, 2026.
Record date for dividend and AGM voting eligibility fixed as July 30, 2026, with the AGM scheduled for August 6, 2026.
Re-appointment of Big 4 firm PwC Services LLP as Internal Auditors for the financial year 2026-27.
Audited financial results for FY 2025-26 approved with an unmodified audit opinion from statutory auditors.
👀 What to Watch
Investors should monitor the company's growth trajectory and potential business transformation under the new CEO's leadership. The Rs. 5.00 dividend provides a steady yield for shareholders ahead of the record date on July 30.
Albert David Appoints New CEO, Recommends Rs 5 Dividend; Record Date July 30
Albert David Limited has appointed Mr. Amit Mahla as the new CEO, bringing over 28 years of pharmaceutical experience from firms like JB Pharma and Sun Pharma. The board recommended a final dividend of Rs 5.00 per share (50% of face value) for FY 2025-26, with July 30, 2026, set as the record date. Financial results for the year ended March 31, 2026, were approved with an unmodified audit opinion. Additionally, the company re-appointed PwC as internal auditors for the upcoming fiscal year.
Key Highlights
Appointment of Mr. Amit Mahla as CEO effective May 12, 2026, with 28+ years of pharma experience.
Recommendation of a final dividend of Rs 5.00 per equity share (50% of face value) for FY26.
Record date for dividend eligibility and 87th AGM voting fixed as July 30, 2026.
Audited financial results for FY26 approved with an unmodified statutory audit report.
Re-appointment of PwC Services LLP as internal auditors for FY 2026-27.
👀 What to Watch
Investors should ensure they hold shares before the July 30 record date to qualify for the Rs 5 dividend and track the impact of the new CEO's leadership on business growth.
Albert David Appoints Amit Mahla as CEO and Recommends Rs 5 Dividend for FY26
Albert David Limited has appointed Mr. Amit Mahla as the new CEO effective May 12, 2026, following the resignation of the previous MD & CEO in late 2025. The Board has recommended a final dividend of 50%, amounting to Rs. 5.00 per equity share for the financial year ended March 31, 2026. Audited financial results for FY26 were approved with an unmodified audit opinion, indicating healthy reporting standards. The company has also fixed July 30, 2026, as the record date for dividend eligibility and the upcoming 87th Annual General Meeting.
Key Highlights
Appointment of Mr. Amit Mahla as CEO, bringing over 28 years of experience from Sun Pharma, JB Pharma, and Cipla.
Recommendation of a final dividend of Rs. 5.00 per share (50% of face value) for FY 2025-26.
Record date for dividend and AGM eligibility set for July 30, 2026.
Re-appointment of PwC Services LLP as Internal Auditors for the financial year 2026-27.
Audited financial results for the quarter and year ended March 31, 2026, received an unmodified audit opinion.
👀 What to Watch
Investors should view the appointment of a seasoned pharma professional as CEO as a positive step toward business transformation. Existing shareholders should ensure they hold the stock by the July 30 record date to qualify for the Rs. 5 dividend.
Albert David Appoints Amit Mahla as CEO and Recommends Rs 5.00 Final Dividend
Albert David Limited has appointed Mr. Amit Mahla as the new CEO effective May 12, 2026, following the earlier resignation of the previous MD & CEO. Mr. Mahla brings over 28 years of experience from major pharmaceutical firms including Sun Pharma, Cipla, and JB Pharma. Alongside this leadership change, the board recommended a final dividend of 50% or Rs 5.00 per share for FY26. The company also confirmed audited financial results for the year ended March 31, 2026, with an unmodified audit opinion.
Key Highlights
Appointment of Mr. Amit Mahla as CEO, a seasoned leader with 28+ years of experience in the Indian Pharmaceutical Market.
Recommendation of a final dividend of Rs 5.00 per equity share (50% of face value) for FY 2025-26.
Record date for dividend eligibility and 87th AGM voting set for July 30, 2026.
Re-appointment of PricewaterhouseCoopers (PwC) Services LLP as Internal Auditors for FY 2026-27.
Audited financial results for FY26 released with an unmodified opinion from statutory auditors.
👀 What to Watch
Investors should view the appointment of a high-profile CEO from top-tier pharma backgrounds as a potential catalyst for growth. The Rs 5.00 dividend provides a steady yield, and the record date of July 30 should be noted for eligibility.
Albert David Appoints Amit Mahla as CEO and Recommends Rs 5.00 Final Dividend
Albert David Limited has appointed Mr. Amit Mahla, a pharmaceutical industry veteran with 28 years of experience, as its new CEO effective May 12, 2026. The Board has recommended a final dividend of 50%, which translates to Rs. 5.00 per equity share for the financial year ended March 31, 2026. The company also reported audited financial results for FY26 with an unmodified audit opinion. Additionally, PwC Services LLP has been re-appointed as internal auditors for the 2026-27 fiscal year.
Key Highlights
Appointment of Mr. Amit Mahla as CEO, who previously held leadership roles at Cipla, Sun Pharma, and JB Pharma.
Recommendation of a final dividend of Rs. 5.00 per share (50% of face value) for FY 2025-26.
Record date for dividend payment and 87th AGM eligibility set for July 30, 2026.
Re-appointment of Big 4 firm PricewaterhouseCoopers Services LLP as Internal Auditors for FY 2026-27.
👀 What to Watch
The appointment of a highly experienced CEO from major pharma backgrounds is a strong positive; investors should monitor for potential business transformation while enjoying the Rs. 5 dividend yield.
Albert David Appoints Amit Mahla as CEO and Recommends Rs 5 Dividend for FY26
Albert David Limited has appointed Mr. Amit Mahla, a pharmaceutical veteran with 28 years of experience, as its new CEO effective May 12, 2026. The Board has recommended a final dividend of 50%, which translates to Rs. 5.00 per equity share for the financial year ended March 31, 2026. The company also approved its audited financial results for FY26 with an unmodified audit opinion from its statutory auditors. Furthermore, the company has re-appointed PwC Services LLP as its internal auditors for the 2026-27 fiscal year.
Key Highlights
Appointment of Mr. Amit Mahla as CEO, who previously held leadership roles at Cipla, Sun Pharma, and JB Pharma.
Recommendation of a final dividend of Rs. 5.00 per equity share (50% of face value) for FY 2025-26.
Record date for dividend payment and 87th AGM eligibility set for July 30, 2026.
Re-appointment of Big 4 firm PricewaterhouseCoopers Services LLP as Internal Auditors for FY 2026-27.
Statutory auditors M/s. L. B. Jha & Co. issued an unmodified audit opinion on the FY26 financial results.
👀 What to Watch
Investors should view the appointment of a seasoned leader like Mr. Mahla as a positive step for potential business transformation. The steady dividend payout of Rs. 5 per share offers a reliable return for existing shareholders.
Albert David Appoints New CEO Amit Mahla; Recommends Rs 5.00 Final Dividend
Albert David Limited has appointed Mr. Amit Mahla as its new CEO, effective May 12, 2026, bringing over 28 years of experience from major pharma firms like Cipla and Sun Pharma. The Board has recommended a final dividend of 50%, which translates to Rs. 5.00 per equity share for the financial year ended March 31, 2026. The company also approved its audited financial results for FY26 with an unmodified audit opinion. Key dates include a record date of July 30, 2026, for dividend eligibility and the AGM scheduled for August 6, 2026.
Key Highlights
Appointment of Mr. Amit Mahla as CEO, a seasoned leader with 28+ years of experience in the Indian Pharmaceutical Market.
Recommendation of a final dividend of Rs. 5.00 per equity share (50% of face value) for FY 2025-26.
Record date for final dividend and AGM voting eligibility fixed as July 30, 2026.
Re-appointment of PricewaterhouseCoopers (PwC) Services LLP as Internal Auditors for FY 2026-27.
👀 What to Watch
Investors should view the leadership change positively given the new CEO's track record in business transformation and brand building. The Rs. 5.00 dividend offers a steady yield; ensure shares are held before the July 30 record date to qualify.
Albert David Recommends Rs 5 Final Dividend and Appoints Amit Mahla as New CEO
Albert David Limited has recommended a final dividend of Rs. 5 per equity share (50% of face value) for the financial year ended March 31, 2026. Alongside the dividend, the company announced the appointment of Mr. Amit Mahla as the new CEO, effective May 12, 2026. Mr. Mahla brings over 28 years of experience from major pharmaceutical firms like Sun Pharma and JB Pharma. The company has fixed July 30, 2026, as the record date for determining dividend eligibility and voting rights for the upcoming 87th AGM.
Key Highlights
Recommended a final dividend of Rs. 5.00 per equity share of Rs. 10 face value (50% payout).
Appointed Mr. Amit Mahla as CEO, who previously held leadership roles at Cipla, Sun Pharma, and JB Pharma.
Fixed July 30, 2026, as the Record Date for dividend payment and AGM eligibility.
The 87th Annual General Meeting (AGM) is scheduled for August 6, 2026.
Re-appointed PricewaterhouseCoopers Services LLP as Internal Auditors for FY 2026-27.
👀 What to Watch
Investors should ensure they hold shares by the record date of July 30, 2026, to qualify for the Rs. 5 dividend. The entry of a seasoned leader from top-tier pharma companies as CEO is a positive signal for potential business transformation.
Albert David Appoints New CEO Amit Mahla; Recommends Rs 5.00 Final Dividend
Albert David Limited has appointed Mr. Amit Mahla as its new CEO, effective May 12, 2026, bringing over 28 years of pharmaceutical experience from firms like Cipla and Sun Pharma. The Board also recommended a final dividend of 50%, amounting to Rs. 5.00 per equity share for the financial year ended March 31, 2026. Financial results for the year were approved with an unmodified audit opinion from M/s. L. B. Jha & Co. The company has set July 30, 2026, as the record date for dividend eligibility and the upcoming 87th Annual General Meeting.
Key Highlights
Appointment of Mr. Amit Mahla as CEO, who previously held leadership roles at JB Pharma and Sun Pharma.
Recommendation of a final dividend of Rs. 5.00 per share (50% of face value) for FY 2025-26.
Record date for the final dividend and 87th AGM voting eligibility fixed as July 30, 2026.
Re-appointment of PwC Services LLP as Internal Auditors for the financial year 2026-27.
Audited financial results for FY26 approved with an unmodified audit opinion from statutory auditors.
👀 What to Watch
Investors should monitor the strategic direction under the new CEO, Mr. Amit Mahla, given his extensive experience in business transformation and the Indian Pharmaceutical Market. The Rs. 5.00 dividend provides a tangible return, and the record date of July 30 should be noted for eligibility.
Albert David Q3 Results: Net Profit at ₹15.30 Cr vs Loss of ₹9.39 Cr YoY; Revenue Up 8%
Albert David Limited reported a significant turnaround in Q3 FY26, posting a net profit of ₹15.30 crore compared to a net loss of ₹9.39 crore in the same period last year. Revenue from operations grew 8.2% YoY to ₹89.93 crore, while sequential growth was also positive. The bottom line was heavily supported by a sharp rise in 'Other Income' which reached ₹12.40 crore. However, on a nine-month basis, the net profit of ₹19.94 crore still lags behind the ₹27.53 crore recorded in the previous year.
Key Highlights
Revenue from operations increased 8.2% YoY to ₹8,992.69 Lakhs from ₹8,308.29 Lakhs.
Net Profit turned positive at ₹1,530.38 Lakhs against a loss of ₹938.78 Lakhs in Q3 FY25.
Other Income spiked to ₹1,239.93 Lakhs compared to a negative ₹900.67 Lakhs in the year-ago period.
Earnings Per Share (EPS) recovered to ₹26.81 from a negative ₹16.45 YoY.
Total expenses for the quarter were lower at ₹8,242.37 Lakhs compared to ₹8,423.69 Lakhs YoY.
👀 What to Watch
Investors should view the return to profitability positively, but must scrutinize the high 'Other Income' component to determine if it is a one-time gain or sustainable. The stock remains a watch to see if operational revenue growth can continue to offset the nine-month performance lag.
Albert David Q3 FY26 Results: Net Profit Swings to ₹15.3 Cr from Loss YoY
Albert David Limited reported a significant turnaround in Q3 FY26, posting a net profit of ₹15.30 crore compared to a net loss of ₹9.39 crore in the same quarter last year. Revenue from operations grew by 8.2% year-on-year to ₹89.93 crore, while total income saw a sharper rise to ₹102.33 crore, aided by a substantial increase in other income. The company's earnings per share (EPS) improved to ₹26.81 from a negative ₹16.45 in the year-ago period. However, for the nine-month period ended December 2025, the net profit of ₹19.94 crore remains lower than the ₹27.53 crore recorded in the corresponding period of the previous year.
Key Highlights
Net Profit of ₹15.30 crore in Q3 FY26 vs a Net Loss of ₹9.39 crore in Q3 FY25.
Revenue from operations increased to ₹89.93 crore from ₹83.08 crore YoY.
Other income surged to ₹12.40 crore, significantly boosting the bottom line compared to negative other income in previous quarters.
9M FY26 profit stands at ₹19.94 crore, down 27.6% compared to ₹27.53 crore in 9M FY25.
Quarterly EPS recovered to ₹26.81 from a loss of ₹16.45 in the previous year's December quarter.
👀 What to Watch
Investors should monitor if the recovery in profitability is sustainable or driven primarily by the surge in 'Other Income'. The turnaround from a loss-making position is a positive signal, but the year-to-date decline in profit suggests overall growth remains under pressure.
